Premium
Pretreated with Evans blue can prevent mast cell degranulation and compound 48/80 induced anaphylaxis
Author(s) -
Chen YuTong,
Lin ShiuanYea,
Lue ShengI,
Lu TzongShi,
Fu YawSyan
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.723.10
Subject(s) - evans blue , degranulation , compound 48/80 , mast cell , pharmacology , medicine , anaphylaxis , chemistry , extravasation , anesthesia , immunology , allergy , receptor
This study demonstrated that pretreated with Evans blue could prevent hypotension, plasma leakage, mesenteric mast cells degranulation induced by compound 48/80, but only prevent mast cells degranulation by substance P. Sprague‐Dawley rats were cannulated for monitoring arterial blood pressure, and femoral vein was cannulated for i.v. injected with substance P (3 μg/kg) and compound 48/80 (200 μg/kg) by syringe pump over 2 min to induced systemic inflammation. Half of animals were pretreated with i.v. injection of a dose of Evans blue (50 mg/kg) 20 sec prior to the drug infusion, and the remaining half of animals were post‐treated with same dose Evans blue after drug infusion immediately. The result of our study showed Evans blue pretreatment could complete inhibit compound 48/80‐induced hypotension, peripheral mast cell degranulation, and edema formation in various organs including the airways, esophagus, and skin. The pretreatment of Evans blue only had few effects on hypotension and plasma leakage induced by substance P, but could prevent the mesenteric mast cell degranulation. In conclusion, Evans blue pretreatment could inhibit the mast cells degranulation and that may be the main mechanism for prevent animals from C48/80‐triggered anaphylaxis and systemic inflammation. Support or Funding Information KMU‐TP104E34, KMU‐O105001